Thalassemia major, as a red blood cell disorder that is passed from both parents to their children, requires high costs and the use of iron chelation drugs throughout the patient's life. Pharmacoeconomics studies in patients with thalassemia major needs to be conducted to determine the efficiency and effectiveness of selecting oral iron chelation drugs. This study aims to analyze the cost and cost-effectiveness of using oral iron chelation drugs such as deferasirox and deferiprone in patients with thalassemia major at RSUP Dr. M. Djamil Padang in 2018-2019. Data was collected retrospectively using total sampling from patient medical records and hospital information system data. Cost parameters include accommodation costs, medical treatment costs, laboratory costs, and drug costs. The effectiveness parameter used is a decrease in serum ferritin levels. Based on the results of this study, the average total cost per treatment for thalassemia major patients who used deferasirox (IDR 401,940,001,-) was more expensive than deferiprone (IDR 269,261,557,-). The effectiveness of deferasirox (1309 ng/mL) was bigger than that of deferiprone (830 ng/mL). The cost-effectiveness ratio of deferasirox (IDR 307,059,-/) was lower than deferiprone (IDR 324,412,-/). To change the drug from deferiprone to deferasirox requires an additional cost of IDR 276,990 per one additional unit. From the average cost-effectiveness ratio, it can be concluded that deferasirox is more cost-effective than deferiprone.

Keywords : Thalassemia Major; Oral Iron Chelation; Cost Effectiveness Analysis; Pharmacoeconomics; Deferasirox; Deferiprone